Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
Status:
Terminated
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The optimal treatment for pretreated patients with metastatic breast cancer has not been
established. Gemcitabine and capecitabine are two active agents in this setting. For women
with Her-2 positive breast cancer, combinations of either gemcitabine or capecitabine
(Xeloda) plus Herceptin has been proved active and well tolerated.